# Who are Celltrion's customers? Who does Celltrion earn revenue from?
Canonical: https://valuechain.wiki/celltrion · Facet: customers · Updated: 2026-07-12T04:19:32.885+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Celltrion discloses no named confirmed revenue counterparties; 3 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 3 revenue edges, backed by 3 dated sources, 1 of them primary filings (as of 2026-07-12).

### 유럽 처방시장 (직접판매) (high)
- metric: Amount 2,009,681 KRW_mn · FY2025 · Consolidated external revenue by region (Europe), net of intercompany
- note: Largest overseas market. FY2025 external European revenue ~KRW 2.0tn. Remsima holds 59% EU share (IQVIA Q3 2025), Remsima SC 30% of EU5. Direct-sales conversion of the full portfolio completed H2 2022.
- [confirms] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "Europe completed full-portfolio direct-sales conversion in H2 2022; Remsima EU share 59% as of Q3 2025."

### 미국·북미 처방시장 (짐펜트라 직접판매) (high)
- metric: Amount 419,963 KRW_mn · FY2025 · Consolidated external revenue by region (North America), +150% vs KRW 168,086mn prior year
- note: Fast-growing market. FY2025 external North America revenue ~KRW 420bn (+150% vs KRW 168bn prior year). Sells Zymfentra, the world's first SC infliximab, directly; ~31% avg monthly prescription growth since the March 2024 launch, and January 2026 prescriptions roughly tripled (+213%) YoY.
- [mentions] Newspim (DS Investment & Securities) (KO, research, published 2026-05-07) https://www.newspim.com/news/view/20260507000043: "DS Investment estimates FY2026 revenue KRW 5,396.5bn (+29.6%) and OP KRW 1,800.4bn (+54.1%), maintaining a KRW 320k target, with new products and US direct sales driving growth."
- [confirms] Seoul Economic Daily (English) (EN, news, published 2026-03-19) https://en.sedaily.com/finance/2026/03/19/celltrions-zymfentra-posts-record-us-prescriptions-in: "Zymfentra's January 2026 US prescriptions rose ~3x (213%) YoY, the steepest growth since its March 2024 launch."
- [confirms] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "In 2023 the US, the world's largest drug market, was converted to direct sales; Zymfentra has grown ~31% in monthly prescriptions on average since its March 2024 launch."

### 국내 처방시장 (셀트리온제약·Primary Care) (mid)
- metric: Amount 1,262,073 KRW_mn · FY2025 · Consolidated external revenue by region (Korea), net of intercompany
- note: FY2025 external domestic revenue ~KRW 1.26tn, including Celltrion Pharm Cheongju chemical output and Takeda-acquired Primary Care brands (Nesina, Actos for diabetes; Edarbi for hypertension).
- [confirms] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "Regional revenue (Korea) and continued domestic rights to 3 Takeda-acquired Primary Care prescription brands (Nesina, Actos, Edarbi)."

Reverse side: https://valuechain.wiki/celltrion/suppliers.md · Ripple: https://valuechain.wiki/celltrion/ripple.md

---
Full node: https://valuechain.wiki/celltrion.md · JSON: https://valuechain.wiki/celltrion.json